<DOC>
	<DOC>NCT03072576</DOC>
	<brief_summary>Consenting adults presenting with signs and symptoms compatible with pulmonary tuberculosis will be interviewed for demographic and medical information, and then will be asked to provide 3-4 expectorated sputum specimens. In the study laboratory, sputa will be tested using conventional and investigational diagnostic tests for tuberculosis and rifampin resistance.</brief_summary>
	<brief_title>Accuracy and Feasibility of Xpert Ultra</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis, Pulmonary</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Case Detection Group Age 18 years or above; Provision of informed consent; Willingness to provide 4 sputum specimens at enrolment; Willingness to have a study followup visit approximately 42 to 70 days after enrolment Clinical suspicion of pulmonary TB (including cough ≥2 weeks and at least 1 other symptom typical of TB) Receipt of any dose of TB treatment within 6 months prior to enrolment Participants for whom, at the time of enrolment, the followup visit is judged to be poorly feasible (e.g. individuals planning to relocate) DrugResistant TB Group Age 18 years or above; Provision of informed consent; Willingness to provide 4 sputum specimens at enrolment; Nonconverting pulmonary TB cases (category I and category II failures) or multidrug resistant (MDR) suspect* (based on World Health Organization definition), i.e. at least one of the following: i) retreatment cases, ii) active TB cases that are MDRcontacts and iii) patients at high risk for MDRTB as determined by local program (e.g. prisoners) • none</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diagnosis</keyword>
	<keyword>Xpert MTB/RIF</keyword>
	<keyword>Ultra Xpert MTB/RIF</keyword>
</DOC>